UCB SA - BNP Paribas Fortis

Rest of World
Zyrtec® (including Cirrus TM ) ............................................... 153 161
Keppra® ............................................................................... 60 41
Xyzal®.................................................................................. 26 22
Nootropil®............................................................................ 24 26
Other products ...................................................................... 140 134
Net Sales Rest of World ...................................................... 404 385
Unallocated………………………………………….. 17 20
Total Net Sales..................................................................... 3,027 3,188
During the first half of 2009, new product launches partially compensated the impact of generic
competition to Keppra® in the U.S. Total revenue decreased as expected by 6% to €1,596 million, and
total net sales amounted to €1,379 million (10% lower than the second half of 2008).
Keppra® reached net sales of €465 million, a 22% decrease by comparison with the second half of
2008, due to post-patent expiry erosion in North America which was mitigated by a significant increase
in sales in Europe, and an increase in sales of 9% in the rest of the world. Sales of Keppra®XR in the
U.S. in the first half of 2009 were €20 million.
Zyrtec® experienced an increase in net sales by 28% to €169 million, due to a number of factors
including an increase of 65 per cent. in sales in Japan following the successful launch of the paediatric
indication in April 2009. However, Xyzal® suffered a decrease of 21% in net sales to €82 million
outside the U.S. largely due to the majority of European countries experiencing a less severe pollen
season. With a mild cough and cold season in the U.S., Tussionex reached net sales of €67 million (a
decrease of 8%). However, Metadate CD, a treatment for attention deficit and hyperactivity disorder,
reached net sales of €42 million (an increase of 15%).
Cimzia®, approved for Crohn’s disease during 2008 in Switzerland and the U.S. and, since May 2009,
approved in the U.S. for patients suffering from moderately to severely active rheumatoid arthritis,
reached net sales of €24 million. Vimpat®, another recently-launched product, reached net sales of €23
million during the first half of 2009. Neupro® showed net sales of €27 million in the first half of 2009,
a decrease of approximately 25%, as a result of UCB effecting a recall from the U.S. market in March
2008, and supply being limited to patients in Europe already receiving the product. Following
remediative steps, Neupro is now restored to full supply in Europe and has also been approved for the
treatment of restless leg syndrome. The Issuer remains in conversation with the FDA regarding further
supply to the U.S., as described in Part 5.5.1. For further information regarding the sales performance
of the Issuer during the first half of 2009, please refer to the Half-Year Report 2009, which is
incorporated into this Offering Circular by reference.
8. RESEARCH AND DEVELOPMENT
(a) Introduction
The vision of the UCB Group is to deliver innovative therapies for patients suffering from severe
central nervous system and immunology disorders. The key features of the research and development
organization of the UCB Group include:
A11250830/2.25/23 Oct 2009 66